POZEN Inc. (POZN: Quote) announced after the bell Wednesday that it has received an Advice/Information Request letter from the FDA. The FDA has made a preliminary review of the study results and POZEN's summary analyses of a Phase 1 study to assess the bioequivalence of PA32540 to enteric-coated aspirin 325 mg using acetylsalicylic acid as the analyte. The FDA does not agree that bioequivalence of PA32540 to EC aspirin 325 mg was demonstrated.
POZEN traded in a narrow range throughout Wednesday's session and closed down by 0.03 at $7.45. The stock is now down 1.29 on 12K shares after the bell.
Click here to receive FREE breaking news email alerts for POZEN Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com